Indian Immunologicals sets up 250-cr plant in Hyd
Indian Immunologicals sets up `250-cr plant in Hyd. Indian Immunologicals Limited (IIL), a leading company in veterinary biologicals and human vaccines, has established Rs 250-crore facility on the city outskirts to manufacture vaccines against infectious diseases of humans and animal health formulations.
Hyderabad: Indian Immunologicals Limited (IIL), a leading company in veterinary biologicals and human vaccines, has established Rs 250-crore facility on the city outskirts to manufacture vaccines against infectious diseases of humans and animal health formulations. The facility, which is located at the third phase of Genome Volley at Karkapatla village in Ranga Reddy district, will cater to the both domestic and international markets.
Operations have already commenced at the new plant. “It is IIL’s second manufacturing unit in Hyderabad. Spread across an area of 47 acres, the plant will significantly expand the company’s manufacturing capabilities,” the company said. The IIL developed this facility, considering the growing demand for the next 10 years for human vaccines and animal health formulations. Human vaccine facility has been established to meet all WHO pre-qualification standards.
The first phase of human vaccine facility at the plant has the capacity to produce 8 million doses of human rabies vaccine. The animal health formulation facility is equipped to produce an estimated capacity of 300 million tablets, 100 million bolus, and 20 million vials of injectables. The plant is equipped with cutting-edge German technology and has fully automated systems consisting of automated granulation, compression lines which have the least possible human intervention.
The unit will provide direct employment to 150 and indirect employment to 300 people. “The facility will strengthen IIL’s position in the industry and will immensely increase our manufacturing capabilities. We are expecting this plant to play a key role in manufacturing top quality vaccines with the most recent German technology,” said Dr K Anand Kumar, Deputy Managing Director, Indian Immunologicals Limited. We will strive to maintain our industry leadership in providing the vaccines in the most affordable prices without compromising on the quality, he added.